Supreme Court Takes Up Appeal Of Post-Mensing Ruling

Law360, New York (November 30, 2012, 7:38 PM EST) -- The U.S. Supreme Court agreed Friday to review the First Circuit's ruling that design defect claims against a generic-drug company are not preempted by federal law, a decision that critics charge is in conflict with the high court's landmark Mensing ruling.

Mutual Pharmaceutical Co. Inc. petitioned the high court to review and reverse a decision upholding a $23 million award to a woman, Karen Bartlett, who suffered a near-fatal reaction after taking Mutual's drug Sulindac for shoulder pain. The First Circuit held that, unlike claims that...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.